Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013, Article ID 454783, 10 pages
http://dx.doi.org/10.1155/2013/454783
Research Article

Synergistic Inhibition of Angiogenesis by Artesunate and Captopril In Vitro and In Vivo

Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, Johannes Gutenberg University, Staudinger Weg 5, 55128 Mainz, Germany

Received 6 June 2013; Revised 15 August 2013; Accepted 20 August 2013

Academic Editor: Shrikant Anant

Copyright © 2013 Benjamin Krusche et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Rosslenbroich, “Understanding the organism as a central problem medicine,” Forsch Komplementarmed Klass Naturheilkd, vol. 8, no. 3, pp. 125–136, 2001. View at Google Scholar
  2. A. M. Leis, L. C. Weeks, and M. J. Verhoef, “Principles to guide integrative oncology and the development of an evidence base,” Current Oncology, vol. 15, supplement 2, pp. s83–s87, 2008. View at Google Scholar
  3. J. Post-White, R. Hawks, A. O'Mara, and M. J. Ott, “Future directions of CAM research in pediatric oncology,” Journal of Pediatric Oncology Nursing, vol. 23, no. 5, pp. 265–268, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Elkins, W. Fisher, and A. Johnson, “Mind-body therapies in integrative oncology,” Current Treatment Options in Oncology, vol. 11, no. 3-4, pp. 128–140, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. D. S. Burns, “Theoretical rationale for music selection in oncology intervention research: an integrative review,” Journal of Music Therapy, vol. 49, pp. 7–22, 2012. View at Google Scholar
  6. A. Running and T. Seright, “Integrative oncology: managing cancer pain with complementary and alternative therapies,” Current Pain and Headache Reports, vol. 16, no. 4, pp. 325–331, 2012. View at Publisher · View at Google Scholar
  7. J. A. Files, D. L. Stan, S. V. Allen, and S. Pruthi, “Chemoprevention of breast cancer,” Womens Health, vol. 8, pp. 635–646, 2012. View at Google Scholar
  8. V. Madka and C. V. Rao, “Anti-inflammatory phytochemicals for chemoprevention of colon cancer,” Current Cancer Drug Targets, vol. 13, no. 5, pp. 542–557, 2013. View at Google Scholar
  9. J. H. Lee, T. O. Khor, L. Shu, Z. Y. Su, F. Fuentes, and A. N. Kong, “Dietary phytochemicals and cancer prevention: Nrf2 signaling, epigenetics, and cell death mechanisms in blocking cancer initiation and progression,” Pharmacology & Therapeutics, vol. 137, pp. 153–171, 2013. View at Publisher · View at Google Scholar
  10. T. Efferth, P. C. H. Li, V. S. B. Konkimalla, and B. Kaina, “From traditional Chinese medicine to rational cancer therapy,” Trends in Molecular Medicine, vol. 13, no. 8, pp. 353–361, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Efferth, Y. J. Fu, Y. G. Zu, G. Schwarz, V. S. B. Konkimalla, and M. Wink, “Molecular target-guided tumour therapy with natural products derived from Traditional Chinese Medicine,” Current Medicinal Chemistry, vol. 14, no. 19, pp. 2024–2032, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Efferth, “Personalized cancer medicine: from molecular diagnostics to targeted therapy with natural products,” Planta Medica, vol. 76, no. 11, pp. 1143–1154, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Efferth, “Stem cells, cancer stem-like cells, and natural products,” Planta Medica, vol. 78, pp. 935–942, 2012. View at Publisher · View at Google Scholar
  14. J. K. Ko and K. K. Auyeung, “Target-oriented mechanisms of novel herbal therapeutics in the chemotherapy of gastrointestinal cancer and inflammation,” Current Pharmaceutical Design, vol. 19, pp. 48–66, 2013. View at Google Scholar
  15. D. L. Klayman, “Qinghaosu (Artemisinin): an antimalarial drug from China,” Science, vol. 228, no. 4703, pp. 1049–1055, 1985. View at Google Scholar · View at Scopus
  16. E. Hsu, “The history of qing hao {A figure is presented} in the Chinese materia medica,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 100, no. 6, pp. 505–508, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. T. You-You, N. Mu-Yun, and Z. Yu-Rong, “Studies on the constituents of Artemisia annua. Part II,” Planta Medica, vol. 44, no. 3, pp. 143–145, 1982. View at Google Scholar · View at Scopus
  18. H. J. Woerdenbag, T. A. Moskal, N. Pras et al., “Cytotoxicity of artemisinin-related endoperoxides to Ehrlich ascites tumor cells,” Journal of Natural Products, vol. 56, no. 6, pp. 849–856, 1993. View at Google Scholar · View at Scopus
  19. J. C. Moore, H. Lai, J. R. Li et al., “Oral administration of dihydroartemisinin and ferrous sulfate retarded implanted fibrosarcoma growth in the rat,” Cancer Letters, vol. 98, no. 1, pp. 83–87, 1995. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Efferth, G. Rücker, M. Falkenberg et al., “Detection of apoptosis in KG-1a leukemic cells treated with investigational drugs,” Drug Research, vol. 46, no. 2, pp. 196–200, 1996. View at Google Scholar · View at Scopus
  21. R. Dell'Eva, U. Pfeffer, R. Vené et al., “Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate,” Biochemical Pharmacology, vol. 68, no. 12, pp. 2359–2366, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. L. N. Li, H. D. Zhang, S. J. Yuan, Z. Y. Tian, L. Wang, and Z. X. Sun, “Artesunate attenuates the growth of human colorectal carcinoma and inhibits hyperactive Wnt/β-catenin pathway,” International Journal of Cancer, vol. 121, no. 6, pp. 1360–1365, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. J. H. Du, H. D. Zhang, Z. J. Ma, and K. M. Ji, “Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo,” Cancer Chemotherapy and Pharmacology, vol. 65, no. 5, pp. 895–902, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. T. G. Berger, D. Dieckmann, T. Efferth et al., “Artesunate in the treatment of metastatic uveal melanoma–first experiences,” Oncology Reports, vol. 14, no. 6, pp. 1599–1603, 2005. View at Google Scholar · View at Scopus
  25. F. H. Jansen, I. Adoubi, K. Comoe J.C et al., “First study of oral artenimol-R in advanced cervical cancer: clinical benefit, tolerability and tumor markers,” Anticancer Research, vol. 31, no. 12, pp. 4417–4422, 2011. View at Google Scholar · View at Scopus
  26. T. Efferth, H. Dunstan, A. Sauerbrey, H. Miyachi, and C. R. Chitambar, “The anti-malarial artesunate is also active against cancer,” International journal of oncology, vol. 18, no. 4, pp. 767–773, 2001. View at Google Scholar · View at Scopus
  27. H. H. Chen, H. J. Zhou, and X. Fang, “Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro,” Pharmacological Research, vol. 48, no. 3, pp. 231–236, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Anfosso, T. Efferth, A. Albini, and U. Pfeffer, “Microarray expression profiles of angiogenesis-related genes predict tumor cell response to artemisinins,” Pharmacogenomics Journal, vol. 6, no. 4, pp. 269–278, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Hou, D. Wang, R. Zhang, and H. Wang, “Experimental therapy of hepatoma with artemisinin and Its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action,” Clinical Cancer Research, vol. 14, no. 17, pp. 5519–5530, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. P. C. H. Li, E. Lam, W. P. Roos, M. Z. Zdzienicka, B. Kaina, and T. Efferth, “Artesunate derived from traditional Chinese medicine induces DNA damage and repair,” Cancer Research, vol. 68, no. 11, pp. 4347–4351, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. L. Steinbrück, G. Pereira, and T. Efferth, “Effects of artesunate on cytokinesis and G2/M cell cycle progression of tumour cells and budding yeast,” Cancer Genomics and Proteomics, vol. 7, no. 6, pp. 337–346, 2010. View at Google Scholar · View at Scopus
  32. N. Berdelle, T. Nikolova, S. Quiros, T. Efferth, and B. Kaina, “Artesunate induces oxidative DNA damage, sustained DNA double-strand breaks, and the ATM/ATR damage response in cancer cells,” Molecular Cancer Therapeutics, vol. 10, no. 12, pp. 2224–2233, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. L. M. Prisant, “Management of hypertension in patients with cardiac disease: use of renin-angiotensin blocking agents,” American Journal of Medicine, vol. 121, no. 8, pp. S8–S15, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. R. DiBianco, “Adverse reactions with angiotensin converting enzyme (ACE) inhibitors,” Medical Toxicology and Adverse Drug Experience, vol. 1, no. 2, pp. 122–141, 1986. View at Google Scholar · View at Scopus
  35. O. V. Volpert, W. F. Ward, M. W. Lingen et al., “Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats,” Journal of Clinical Investigation, vol. 98, no. 3, pp. 671–679, 1996. View at Google Scholar · View at Scopus
  36. B. Vogt and F. J. Frey, “Inhibition of angiogenesis in Kaposi's sarcoma by captopril,” Lancet, vol. 349, no. 9059, p. 1148, 1997. View at Publisher · View at Google Scholar · View at Scopus
  37. P. Carmeliet and R. K. Jain, “Angiogenesis in cancer and other diseases,” Nature, vol. 407, no. 6801, pp. 249–257, 2000. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Giuliano and G. Pages, “Mechanisms of resistance to anti-angiogenesis therapies,” Biochimie, vol. 95, no. 6, pp. 1110–1119, 2013. View at Publisher · View at Google Scholar
  39. O. Wahl, M. Oswald, L. Tretzel, E. Herres, J. Arend, and T. Efferth, “Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products,” Current Medicinal Chemistry, vol. 18, no. 21, pp. 3136–3155, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. P. F. J. W. Rijken, H. J. J. A. Bernsen, and A. J. Van Der Kogel, “Application of an image analysis system to the quantitation of tumor perfusion and vascularity in human glioma xenografts,” Microvascular Research, vol. 50, no. 2, pp. 141–153, 1995. View at Publisher · View at Google Scholar · View at Scopus
  41. H. H. Chen, H. J. Zhou, W. Q. Wang, and G. D. Wu, “Antimalarial dihydroartemisinin also inhibits angiogenesis,” Cancer Chemotherapy and Pharmacology, vol. 53, no. 5, pp. 423–432, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. S. R. Meshnick, “Artemisinin: mechanisms of action, resistance and toxicity,” International Journal for Parasitology, vol. 32, no. 13, pp. 1655–1660, 2002. View at Publisher · View at Google Scholar · View at Scopus
  43. U. Eckstein-Ludwig, R. J. Webb, I. D. A. Van Goethem et al., “Artemisinins target the SERCA of Plasmodium falciparum,” Nature, vol. 424, no. 6951, pp. 957–961, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. P. H. Jones, K. Christodoulos, N. Dobbs et al., “Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer,” British Journal of Cancer, vol. 91, no. 1, pp. 30–36, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. S. I. Hii, D. L. Nicol, D. C. Gotley, L. C. Thompson, M. K. Green, and J. R. Jonsson, “Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma,” British Journal of Cancer, vol. 77, no. 6, pp. 880–883, 1998. View at Google Scholar · View at Scopus
  46. O. Al-Shabanah, M. Mansour, H. El-Kashef, and A. Al-Bekairi, “Captopril ameliorates myocardial and hematological toxicities induced by adriamycin,” Biochemistry and Molecular Biology International, vol. 45, no. 2, pp. 419–427, 1998. View at Google Scholar · View at Scopus
  47. I. Müller, D. Niethammer, and G. Bruchelt, “Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity (Review),” International Journal of Molecular Medicine, vol. 1, no. 2, pp. 491–494, 1998. View at Google Scholar · View at Scopus
  48. T. Efferth and B. Kaina, “Toxicity of the antimalarial artemisinin and its dervatives,” Critical Reviews in Toxicology, vol. 40, no. 5, pp. 405–421, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. J. B. Christian, K. L. Lapane, A. L. Hume, C. B. Eaton, and M. A. Weinstock, “Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial,” Journal of the National Cancer Institute, vol. 100, no. 17, pp. 1223–1232, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. R. Yasumatsu, T. Nakashima, M. Masuda et al., “Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells,” Journal of Cancer Research and Clinical Oncology, vol. 130, no. 10, pp. 567–573, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. V. Fendrich, N. M. Chen, M. Neef et al., “The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer,” Gut, vol. 59, no. 5, pp. 630–637, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. S. L. Amaral, P. E. Papanek, and A. S. Greene, “Angiotensin II and VEGF are involved in angiogenesis induced by short-term exercise training,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 281, no. 3, pp. H1163–H1169, 2001. View at Google Scholar · View at Scopus
  53. S. Attoub, A. M. Gaben, S. Al-Salam et al., “Captopril as a potential inhibitor of lung tumor growth and metastasis,” Annals of the New York Academy of Sciences, vol. 1138, pp. 65–72, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. D. A. Walsh, D. E. Hu, J. Wharton, J. D. Catravas, D. R. Blake, and T. P. D. Fan, “Sequential development of angiotensin receptors and angiotensin I converting enzyme during angiogenesis in the rat subcutaneous sponge granuloma,” British Journal of Pharmacology, vol. 120, no. 7, pp. 1302–1311, 1997. View at Publisher · View at Google Scholar · View at Scopus
  55. T. Efferth, M. Marschall, X. Wang et al., “Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses,” Journal of Molecular Medicine, vol. 80, no. 4, pp. 233–242, 2002. View at Publisher · View at Google Scholar · View at Scopus
  56. B. Bachmeier, I. Fichtner, P. H. Killian, E. Kronski, U. Pfeffer, and T. Efferth, “Development of resistance towards artesunate in MDA-MB-231 human breast cancer cells,” PLoS ONE, vol. 6, no. 5, Article ID e20550, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. H. H. Chen, H. J. Zhou, G. D. Wu, and X. E. Lou, “Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1,” Pharmacology, vol. 71, no. 1, pp. 1–9, 2004. View at Publisher · View at Google Scholar · View at Scopus
  58. C. Huan-Huan, Y. Li-Li, and L. Shang-Bin, “Artesunate reduces chicken chorioallantoic membrane neovascularisation and exhibits antiangiogenic and apoptotic activity on human microvascular dermal endothelial cell,” Cancer Letters, vol. 211, no. 2, pp. 163–173, 2004. View at Publisher · View at Google Scholar · View at Scopus
  59. J. Kowalski and Z. S. Herman, “Captopril augments antitumor activity of cyclophosphamide in mice,” Polish Journal of Pharmacology, vol. 48, no. 3, pp. 281–285, 1996. View at Google Scholar · View at Scopus
  60. J. R. Merchan, B. Chan, S. Kale, L. E. Schnipper, and V. P. Sukhatme, “In vitro and in vivo induction of antiangiogenic activity by plasminogen activators and captopril,” Journal of the National Cancer Institute, vol. 95, no. 5, pp. 388–399, 2003. View at Google Scholar · View at Scopus
  61. R. R. J. de Groot-Besseling, T. J. M. Ruers, A. A. Van Kraats et al., “Anti-tumor activity of a combination of plasminogen activator and captopril in a human melanoma xenograft model,” International Journal of Cancer, vol. 112, no. 2, pp. 329–334, 2004. View at Publisher · View at Google Scholar · View at Scopus
  62. C. Prontera, B. Mariani, C. Rossi, A. Poggi, and D. Rotilio, “Inhibition of gelatinase A, (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma,” International Journal of Cancer, vol. 81, no. 5, pp. 761–766, 1999. View at Google Scholar